Expertise in
10
conditions

Dr. Patricia L. Rich

Oncology
Patricia Rich,Md
600 Celebrate Life Pkwy, 
Newnan, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Patricia Rich,Md
600 Celebrate Life Pkwy, 
Newnan, GA 

Overview

Patricia Rich is an Oncologist practicing medicine in Newnan, Georgia.

Dr. Rich is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Squamous Cell Lung Carcinoma.

She is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 7 clinical trials. Dr. Rich is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IL

Hospital Affiliations

Parkview Dekalb Hospital
Parkview Whitley Hospital
Parkview Regional Medical Center
Parkview Noble Hospital
Parkview Wabash Hospital, Inc

Languages Spoken

English
Hindi
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Patricia Rich,Md
600 Celebrate Life Pkwy, Newnan, GA 30265

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Terminated
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Enrollment Status: Terminated
Publish Date: June 28, 2023
Intervention Type: Drug
Study Drug: Tarloxotinib bromide
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
View 6 Less Clinical Trials

9 Total Publications

Reply to P. de Boissieu et al.
Reply to P. de Boissieu et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 09, 2024
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

City Of Hope Atlanta Cancer Center

600 Celebrate Life Pkwy, 
Newnan, GA 
 (0.1 miles away)
877-461-2997
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leslie Popplewell is an Oncologist practicing medicine in Newnan, Georgia. Dr. Popplewell is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Popplewell is currently accepting new patients.

Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Referral may be required

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (33.5 miles away)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (37.6 miles away)
404-778-1900
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Suresh Ramalingam is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Ramalingam is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Ramalingam is board certified in American Board Of Internal Medicine, 2003. Dr. Ramalingam is currently accepting new patients.

Frequently Asked Questions about Dr. Patricia L. Rich

How do I make an appointment with Dr. Patricia L. Rich?

You can book an appointment with Dr. Patricia L. Rich by calling their office at 847-342-6910. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Patricia L. Rich a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Patricia L. Rich is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Patricia L. Rich specialize in?

While Dr. Patricia L. Rich is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Patricia L. Rich participate in research or clinical trials?

Yes. Dr. Patricia L. Rich has published 9 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Patricia L. Rich's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Patricia L. Rich accept my insurance?

Dr. Patricia L. Rich accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 847-342-6910 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rich's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile